The sponsorship serves as a symbolic nod to the nearly five-decade gap in medical innovation for motion-induced vomiting. As the first new prescription medication approved for this condition in 47 years, NEREUS—tradipitant—aims to provide a modern pharmacological option for travelers. The branded vehicle will appear at select events throughout the 2026 season.

Mihael H. Polymeropoulos, President and CEO of Vanda, noted that the collaboration reflects a shared commitment to maintaining performance under extreme conditions. While the pharmaceutical company focuses on addressing unmet medical needs, the high-speed environment of IndyCar provides a platform to highlight the drug's role in stability and focus. The move underscores Vanda’s strategy to bridge clinical advancement with high-profile public visibility.